Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Journal Scan / Research · June 22, 2021

5-Year Survival With Pembrolizumab vs Docetaxel for Previously Treated, PD-L1–Positive Advanced NSCLC

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1–Positive Advanced Non–Small-Cell Lung Cancer
J Thorac Oncol 2021 May 25;[EPub Ahead of Print], RS Herbst, EB Garon, DW Kim, BC Cho, R Gervais, JL Perez-Gracia, JY Han, M Majem, MD Forster, I Monnet, S Novello, MA Gubens, M Boyer, WC Su, A Samkari, EH Jensen, J Kobie, B Piperdi, P Baas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading